Corbus Pharmaceuticals (NASDAQ:CRBP) Now Covered by B. Riley

Research analysts at B. Riley assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $85.00 price target on the biopharmaceutical company’s stock. B. Riley’s price objective would suggest a potential upside of 93.71% from […]

Leave a Reply

Your email address will not be published.

Previous post PagSeguro Digital (NYSE:PAGS) Rating Increased to Buy at The Goldman Sachs Group
Next post Comparing Sarepta Therapeutics (NASDAQ:SRPT) and ANI Pharmaceuticals (NASDAQ:ANIP)